Licensing Arrangement, Milestone, Maximum, Value

No definition available.

Name:	pfe_LicensingArrangementMilestoneMaximumValue
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Licensing Arrangement, Number Of Shares Purchased

+ References

No definition available.

+ Details

Name:	pfe_LicensingArrangementNumberOfSharesPurchased
Namespace Prefix:	pfe_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Licensing Arrangement, Value Of Shares Purchased

+ References

No definition available.

+ Details

Name:	pfe_LicensingArrangementValueOfSharesPurchased
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment For Licensing Arrangement

+ References

No definition available.

+ Details

Name:	pfe_PaymentForLicensingArrangement
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage
Namespace Prefix:	pfe_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Commercialization Milestones, Maximum Exposure

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development Arrangement, Contingent Payments, Maximum Exposure1

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development Arrangement, Development Milestone, Maximum Exposure

+ References

No definition available.

+ Details

Name:	pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=pfe_ValnevaSEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pfe_BioNTechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details) - USD ($) $ in Millions		1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 04, 2019	Nov. 30, 2019	Sep. 30, 2018	Jun. 28, 2020	Sep. 30, 2018	Dec. 31, 2020	Apr. 30, 2020
Valneva [Member] \| Licensing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential cash payments							$ 308
Potential development milestones							35
Potential early commercialization milestones							$ 143
Development cost ownership percentage						30.00%
Valneva [Member] \| Research and Development Expense [Member] \| Licensing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing arrangement				$ 130
Licensing Agreements [Member] \| BioNTech [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Licensing arrangement, maximum potential milestones			$ 325
Licensing Agreements [Member] \| BioNTech [Member] \| Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing arrangement			$ 50
Licensing Agreements [Member] \| Akcea And Ionis [Member] \| Research and Development Expense [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing arrangement		$ 250
Licensing arrangement, maximum potential milestones	$ 1,300
Long-term Investments [Member] \| Licensing Agreements [Member] \| BioNTech [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased					169,670
Value of shares purchased					$ 50